# Metformin and Sitagliptin Impact the Brain Kynurenine Pathway: Region-Specific Modulation of Neuroactive Metabolites in Non-Diabetic Male Rats

**Authors:** Kinga Bednarz, Renata Kloc, Tymoteusz Słowik, Ewa M. Urbanska

PMC · DOI: 10.3390/molecules31040714 · Molecules · 2026-02-19

## TL;DR

The study shows that metformin and sitagliptin affect brain metabolites involved in the kynurenine pathway differently in various brain regions of non-diabetic rats.

## Contribution

This study reveals region-specific modulation of the TRP-KYN pathway by metformin and sitagliptin in the brain.

## Key findings

- Metformin reduced cortical TRP and KYNA, hippocampal KYN, and cerebellar kynurenines.
- Sitagliptin did not alter kynurenine levels but both drugs affected TRP/KYN or KYN/KYNA ratios.
- Metformin increased KYNA in the striatum while decreasing it in the cortex.

## Abstract

An excessive activation of the tryptophan–kynurenine (TRP-KYN) pathway, frequently observed in metabolic and inflammatory disorders, leads to disturbances in the balance between neurotoxic and neuroprotective metabolites. These alterations may contribute to neuronal dysfunction and cognitive impairment, highlighting the importance of modulating this pathway in the context of neuroprotection. Metformin, apart from the AMPK activation and its broad anti-inflammatory actions, has been indicated as a drug capable of influencing the synthesis of TRP metabolites, including the neuroprotective kynurenic acid (KYNA), whereas the effects of sitagliptin in this regard are not known. Here, the effects of sub-chronic metformin or sitagliptin treatment on the brain levels of kynurenines and on functional alterations within the TRP-KYN pathway were evaluated in vivo, in adult non-diabetic Wistar male rats. A 5-day treatment with metformin decreased cortical TRP and KYNA, hippocampal KYN, and cerebellar levels of all studied kynurenines, whereas in the striatum, KYNA level increased. In contrast, sitagliptin did not alter the formation of kynurenines in the examined structures. However, both of the tested drugs had a significant impact on TRP/L-KYN or L-KYN/KYNA ratios in different parts of the brain. These findings indicate a prominent region-specific effect of metformin on brain kynurenines. In conclusion, commonly used antidiabetic agents differ in their impact on central TRP metabolism, which may have significant implications for understanding their potential neuroprotective effects and role in cognitive impairment.

## Linked entities

- **Chemicals:** Metformin (PubChem CID 4091), Sitagliptin (PubChem CID 4369359), kynurenic acid (PubChem CID 3845), TRP (PubChem CID 6305), KYNA (PubChem CID 3845), KYN (PubChem CID 161166)

## Full-text entities

- **Genes:** Aadat (aminoadipate aminotransferase) [NCBI Gene 23923] {aka Aadt, KATII, Kat2, Kyat2, mKat-2}, TDO2 (tryptophan 2,3-dioxygenase) [NCBI Gene 6999] {aka HYPTRP, TDO, TO, TPH2, TRPO}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Nek1 (NIMA (never in mitosis gene a)-related expressed kinase 1) [NCBI Gene 18004] {aka D8Ertd790e, kat}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Mir141 (microRNA 141) [NCBI Gene 100314215] {aka rno-mir-141}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IDO1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 3620] {aka IDO, IDO-1, INDO}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, Kmo (kynurenine 3-monooxygenase) [NCBI Gene 98256], GIP (gastric inhibitory polypeptide) [NCBI Gene 2695], IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, DPP4 (dipeptidyl peptidase 4) [NCBI Gene 1803] {aka ADABP, ADCP2, CD26, DPPIV, TP103}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Grin1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 24408] {aka GluN1, NMDAR1, NR1}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, Prkaa2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 78975] {aka Ampk, Ampka2}, App (amyloid beta precursor protein) [NCBI Gene 54226] {aka Abeta}, Ahr (aryl hydrocarbon receptor) [NCBI Gene 25690], Gpr35 (G protein-coupled receptor 35) [NCBI Gene 367315]
- **Diseases:** neurodegeneration (MESH:D019636), injury to (MESH:D014947), inflammation (MESH:D007249), Parkinson's disease (MESH:D010300), mitochondrial dysfunction (MESH:D028361), memory decline (MESH:D060825), Alzheimer's disease (MESH:D000544), neurotoxic (MESH:D020258), Diabetic (MESH:D003920), traumatic brain injury (MESH:D000070642), neuroinflammation (MESH:D000090862), obesity (MESH:D009765), impaired memory and learning (MESH:D007859), neuronal dysfunction (MESH:D009461), metabolic (MESH:D008659), brain disorders (MESH:D001927), sleep deprivation (MESH:D012892), neuronal damage (MESH:D009410), breast cancer (MESH:D001943), dementia (MESH:D003704), synaptic dysfunction (MESH:C536122), glucose intolerance (MESH:D018149), cognitive decline (MESH:D003072)
- **Chemicals:** zinc acetate (MESH:D019345), KYNA (MESH:D007736), Sitagliptin (MESH:D000068900), acetonitrile (MESH:C032159), L (MESH:D007930), xanthurenic acid (MESH:C028330), water (MESH:D014867), Metformin (MESH:D008687), 5-HTP (MESH:D006916), KYN (MESH:D007737), glutamate (MESH:D018698), 3-HK (MESH:C005045), vildagliptin (MESH:D000077597), glycine (MESH:D005998), QUIN (MESH:D017378), Ca2+ (-), melatonin (MESH:D008550), amino-acid (MESH:D000596), 3-HANA (MESH:D015095), strychnine (MESH:D013331), sodium acetate (MESH:D019346), NAD+ (MESH:D009243), TRP (MESH:D014364), HClO4 (MESH:C576518), serotonin (MESH:D012701), DMSO (MESH:D004121), reactive oxygen species (MESH:D017382)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943256/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943256/full.md

## References

77 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943256/full.md

---
Source: https://tomesphere.com/paper/PMC12943256